

ADVANCES IN OCULAR DRUG DELIVERY SYSTEMS FOR THE TREATMENT AND MANAGEMENT OF CATARACTS: A REVIEW

**Snigdha S Babu^{a*}, Sanil Kumar R^b, Shaiju S Dharan^c, K.L.Krishna Kumar^d, Deepthi Swapna P.R^e,
Ashwini Badakundri^f**

^aResearch Scholar , Department of Pharmacy ,Annamalai University, Tamilnadu

^bAssistant Professor , Department of Pharmacy , Annamalai University, Tamilnadu

^cPrincipal, Ezhuthachan College of Pharmaceutical Sciences, Kerala

^dProfessor , Aditya Bangalore Institute of Pharmacy Education and Research , Bangalore

^eAssistant Professor , Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore

^fAssistant Professor , Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore

***Corresponding Author: Snigdha S Babu**

Email: snigdhasatheesababu@gmail.com

Abstract

Cataracts remain the leading cause of visual impairment worldwide, primarily managed through surgical intervention. However, growing interest in pharmacological strategies for prevention and adjunct therapy has propelled innovation in ocular drug delivery systems. This review outlines the pathophysiology of cataracts, evaluates the limitations of conventional treatment methods, and presents recent advancements in drug delivery systems, including nanoparticles, liposomes, in situ gels, contact lenses, and microneedles. These systems offer targeted, sustained, and non-invasive delivery of therapeutic agents, potentially transforming cataract management.

Keywords: Cataract, ocular drug delivery, nanoparticles, liposomes, microneedles, sustained release


1.Introduction

Cataracts remain a leading cause of visual impairment and blindness worldwide, particularly among aging populations. While surgical intervention is currently the primary and most effective treatment, it presents several challenges such as limited accessibility in low-resource settings, high surgical costs, and the risk of postoperative complications including posterior capsule opacification and infection [1]. As a result, there has been increasing interest in pharmacological therapies as alternative or adjunctive options for managing cataracts, especially during the early stages of disease progression [2].

However, effective ocular drug delivery remains a significant challenge due to the unique anatomical and physiological barriers of the eye, including the corneal epithelium, blood-aqueous barrier, and rapid tear turnover, all of which limit drug bioavailability and penetration to intraocular tissues [3]. Conventional topical formulations such as eye drops exhibit poor ocular retention and rapid precorneal elimination, resulting in minimal therapeutic efficacy for lens-targeted treatments [4].


To address these limitations, recent advancements in ocular drug delivery systems have focused on developing innovative platforms capable of enhancing drug bioavailability, providing sustained release, and achieving targeted delivery to specific ocular tissues. Among these, nanotechnology-based approaches such as nanoparticles, nanoemulsions, and nanomicelles have demonstrated considerable potential in improving drug penetration and retention within ocular structures [5]. Polymeric nanoparticles composed of biodegradable carriers like poly(lactic-co-glycolic acid) (PLGA) have shown favorable pharmacokinetic profiles, controlled release properties, and improved lens targeting capabilities [6].

Additionally, novel delivery systems including in situ forming gels, microneedle-based devices, ocular inserts, and implantable devices are being explored to prolong ocular drug residence time and improve therapeutic outcomes in cataract management [7]. These technologies aim to overcome ocular barriers, reduce dosing frequency, and enhance patient compliance, particularly in chronic ophthalmic diseases [8]. This review aims to provide a comprehensive overview of recent advances in ocular drug delivery systems specifically for the treatment and management of cataracts, highlighting novel formulations, delivery strategies, their mechanisms, and their potential translational applications in clinical ophthalmology [9].



2.Mechanisms of Cataract Formation

Cataract is characterized by the progressive opacification of the crystalline lens, leading to impaired vision. The mechanisms of cataractogenesis are multifactorial, involving biochemical, genetic, and environmental factors.



2.1 Oxidative Stress and Free Radical Damage

The lens is continuously exposed to oxidative insults from UV radiation and metabolic processes. Accumulation of reactive oxygen species (ROS) damages lens proteins, lipids, and DNA, leading to protein aggregation and lens opacity. Depletion of antioxidants like glutathione (GSH) plays a pivotal role in cataract formation.[10]

2.2 Protein Aggregation and Crystallin Modification

Lens transparency depends on the solubility and stability of crystallin proteins. Post-translational modifications (glycation, oxidation, deamidation) cause protein unfolding, aggregation, and formation of high molecular weight (HMW) insoluble proteins. This light-scattering aggregation leads to lens opacity.

2.3 Glycation and Advanced Glycation End Products (AGEs)

In diabetic and age-related cataracts, elevated glucose leads to non-enzymatic glycation of lens proteins. Formation of AGEs contributes to protein cross-linking and insolubility[12].

2.4 Calcium Dysregulation and Activation of Calpains

Increased intra-lenticular calcium levels activate calpains (calcium-dependent cysteine proteases). Calpains degrade crystallins and other cytoskeletal proteins, leading to cataract formation.[13]

2.5 Genetic and Congenital Factors

Mutations in genes encoding crystallins, membrane proteins, and connexins have been linked to congenital and early-onset cataracts. Disruption in lens fiber cell differentiation and homeostasis contributes to cataract formation.[14]

2.6 UV Radiation-Induced Damage

UVB radiation directly damages DNA and proteins in the lens. Indirectly generates ROS, exacerbating oxidative stress and protein aggregation.

Cataractogenesis is a result of complex, interrelated biochemical and molecular events, modulated by environmental exposures and genetic susceptibility. Emerging therapies target these pathways to delay or prevent cataract formation.[15]

3. Barriers to Ocular Drug Delivery

The eye is a highly protected and complex organ with multiple anatomical and physiological barriers that significantly limit the bioavailability of topically or systemically administered drugs intended for intraocular tissues. Key barriers include the tear film, corneal epithelium, conjunctival blood flow, and blood-ocular barriers, such as the blood-aqueous and blood-retinal barriers, which regulate drug permeation and protect sensitive ocular structures from foreign substances. Topical formulations, though widely used due to patient convenience, typically achieve less than 5% ocular bioavailability because of rapid precorneal elimination through blinking, tear turnover, and nasolacrimal drainage. Moreover, the corneal epithelium, with its tight junctions and lipophilic nature, poses a formidable obstacle to hydrophilic and macromolecular drugs, while systemic administration is limited by the restrictive permeability of the blood-ocular barriers. These physiological defense mechanisms, although essential for ocular health, create significant challenges for achieving therapeutic drug concentrations within the lens and other intraocular tissues, necessitating the development of advanced delivery strategies capable of bypassing or overcoming these obstacles for effective cataract pharmacotherapy [1].

4. Novel Ocular Drug Delivery Systems for the treatment and management of cataract

4.1 Nanoparticles

Nanoparticles offer improved penetration and controlled drug release profiles. These systems protect labile drugs from degradation and enhance their residence time in ocular tissues. Recent advancements in nanotechnology have introduced innovative strategies for cataract prevention and treatment, focusing on enhancing drug delivery and mitigating oxidative stress within the lens. One notable development is the creation of ceria nanoparticles modified with cyclic cell-penetrating peptides (cCPPs), which have demonstrated improved trans-corneal transport and mitochondrial targeting. These nanoparticles effectively counteract ferroptosis induced by oxidative stress in lens epithelial cells, substantially reducing cataract formation in both in vitro and in vivo models [16].

Another significant approach involves the use of gold nanoparticles encapsulating resveratrol, a compound known for its antioxidant properties. This formulation has shown potential in delaying cataract development by reducing oxidative stress in lens epithelial cells. Additionally, aspirin-derived nanorods have been developed to prevent the aggregation of crystallin

proteins, a key factor in cataractogenesis. These nanorods inhibit protein aggregation through biomolecular interactions, offering a non-invasive and economical strategy for cataract prevention[17].

Furthermore, polymeric nanomicelles have emerged as promising carriers for delivering therapeutic agents to the eye. Their ability to enhance drug solubility and stability, along with improved penetration through ocular barriers, makes them suitable for treating various eye diseases, including cataracts[18].

4.2 Liposomes

Liposomes, composed of phospholipid bilayers, mimic biological membranes and are biocompatible. They enhance solubility of hydrophobic drugs and provide sustained release. Liposomal delivery is especially beneficial in reducing dosing frequency and minimizing systemic exposure. Recent advancements in liposome-based drug delivery systems have shown significant promise in the prevention and treatment of cataracts. Liposomes, due to their biocompatibility and ability to encapsulate both hydrophilic and hydrophobic drugs, offer a versatile platform for ocular drug delivery. For instance, Wang et al. developed chitosan-coated liposomal eye drops capable of delivering both hydrophilic ganciclovir and hydrophobic curcumin to the posterior segment of the eye. The chitosan coating enhanced mucin binding and facilitated the temporary opening of tight junctions in corneal and conjunctival epithelial cells, thereby improving drug retention and penetration. This formulation demonstrated significant therapeutic efficacy in animal models, suggesting its potential for non-invasive cataract treatment[19]

In another study, Gu et al. formulated trimethylated chitosan-coated flexible liposomes loaded with resveratrol for topical ocular delivery. These liposomes effectively reduced blue-light-induced retinal damage, highlighting their potential in cataract prevention strategies[20]. Additionally, Zhou et al. discussed the use of liposomes encapsulating platinum nanozymes to counteract reactive oxygen species (ROS), a major contributor to cataract formation. These liposomes exhibited enhanced bioavailability and sustained drug release, making them suitable for long-term ocular therapies [21]. Furthermore, a review by Tang et al. emphasized the role of liposomes in improving ocular drug delivery by enhancing drug permeability and reducing toxic side effects, thereby offering a promising approach for cataract management[22]

4.3 In Situ Gels

In situ forming gels transition from liquid to gel upon ocular instillation due to stimuli such as temperature or pH. These systems prolong residence time and enhance ocular bioavailability. Chaudhuri et al. developed a pH-triggered in situ gel incorporating kaempferol using pectin and HPMC K4M. This formulation aimed to enhance ocular residence time and provide controlled drug release. In vitro evaluations demonstrated favorable rheological properties and sustained drug release. Furthermore, in vivo studies using a sodium selenite-induced cataract model in Wistar rat pups indicated significant anti-cataract activity, suggesting the formulation's potential in cataract management[23].

In another study, Kotreka et al. formulated an ion-activated in situ gel containing estradiol using gellan gum. The gelation occurred upon contact with simulated tear fluid, forming a gel that released the drug over an extended period. The formulation exhibited suitable pH, clarity, and rheological behavior, and remained stable over six months. In vitro release studies showed that 80% of estradiol was released within 8 hours, indicating the system's potential for preventing age-related cataracts[24].

Additionally, Gözcü et al. developed a hesperidin-loaded in situ gel using poloxamer and hydroxyethyl cellulose. The formulation demonstrated appropriate viscosity, shear-thinning behavior, and sustained drug release, enhancing ocular bioavailability and residence time [25]


4.4 Contact Lens-Based Delivery

Therapeutic contact lenses are emerging as non-invasive platforms for continuous drug delivery. Drug-loaded lenses using molecular imprinting and nanoparticle embedding can sustain release for several days, improving patient compliance and therapeutic outcomes . This system provides a unique opportunity for prolonged delivery without disrupting vision. Kumara et al. developed chitosan-based nanocomposite contact lenses capable of delivering single (latanoprost) and dual (latanoprost-timolol) anti-glaucoma medications in response to lysozyme present in tear fluid. These lenses exhibited over 80% transparency, maintained mechanical integrity, and achieved substantial drug release over 72 hours, indicating their efficacy in maintaining intraocular pressure with minimal irritation in rabbit models [26]. Similarly, Guo et al. formulated levofloxacin-loaded silicone contact lenses, demonstrating effective antibacterial activity and sustained drug release, highlighting their potential in treating ocular infections[27]. Torun et al. explored microfluidic contact lenses, integrating microchannels within the lens structure to facilitate controlled drug delivery and real-time monitoring of ocular biomarkers, representing a significant step towards personalized ocular therapy[28]. These innovative approaches underscore the versatility of contact lenses as drug delivery platforms, offering improved bioavailability, patient compliance, and therapeutic outcomes. The integration of nanomaterials and microfluidic systems within contact lenses not only enhances drug loading and release profiles but also opens avenues for simultaneous diagnosis and treatment of ocular diseases. As research progresses, these multifunctional contact lenses hold promise for revolutionizing the management of various eye conditions, including cataracts, by providing non-invasive, sustained, and targeted drug delivery solutions.

4.5 Microneedles

Microneedles bypass the corneal barrier and enable direct delivery to intraocular tissues with minimal invasiveness. These systems hold promise for delivering macromolecules directly to the lens or posterior chamber. For instance, Fitaihi et al. developed a dissolving microneedle array for transscleral delivery of dexamethasone-loaded microparticles, achieving sustained drug release and significant therapeutic effects in ocular inflammation models [29]. Similarly, Wu et al. designed rapidly dissolving bilayer microneedles enabling efficient protein delivery to the posterior segment, demonstrating enhanced bioavailability and reduced administration frequency[30]. Additionally, Shi et al. formulated a dissolvable hybrid microneedle patch for curcumin delivery, effectively reducing intraocular inflammation in experimental models[31].

These advancements underscore the potential of MNs in overcoming the limitations of conventional ocular drug delivery methods. By facilitating targeted, controlled, and sustained release of therapeutics, MNs can enhance treatment efficacy while minimizing systemic side effects. The versatility in MN design, including dissolvable and bilayer structures, allows for customization based on specific drug properties and therapeutic requirements. As research progresses, the integration of MN technology into clinical practice holds promise for improving the management of various ocular diseases, including cataracts.



5.Challenges and Future Directions

Despite significant advancements in the development of ocular drug delivery systems for cataract treatment, several challenges persist that hinder their clinical translation and widespread adoption. Achieving adequate drug concentrations at the lens remains difficult due to the eye's protective barriers, rapid precorneal elimination, and limited permeability of conventional formulations. Additionally, the long-term safety, biocompatibility, and potential toxicity of novel delivery vehicles such as nanoparticles, liposomes, and microneedles require extensive investigation through preclinical and clinical studies. Regulatory approval processes for innovative ocular therapeutics are also complex, as sustained-release systems and nanotechnology-based platforms demand rigorous evaluation of their pharmacokinetics, ocular tolerability, and stability. Looking ahead, future research should focus on developing minimally invasive, patient-friendly delivery approaches that ensure targeted, controlled, and prolonged drug release to the lens. Furthermore, combining pharmacological strategies with early diagnostic techniques and personalized medicine could enhance treatment outcomes and delay or prevent the progression of cataracts in at-risk populations [32].

6.Conclusion

Cataracts continue to be the primary cause of visual impairment globally, with surgical intervention remaining the only definitive treatment. However, challenges such as limited surgical access in resource-limited settings, postoperative complications, and rising global prevalence have underscored the need for alternative and adjunctive therapeutic approaches. Pharmacological strategies aimed at preventing or slowing cataract progression have gained increasing attention, particularly as our understanding of cataract pathophysiology—spanning oxidative stress, protein aggregation, and metabolic dysregulation—has advanced. Recent innovations in ocular drug delivery systems have addressed many of the limitations of conventional therapies, including poor ocular bioavailability and rapid drug elimination. Nanoparticles, liposomes, in situ gels, therapeutic contact lenses, and microneedles have demonstrated the potential to deliver therapeutic agents in a targeted, sustained, and non-invasive manner. These platforms enhance drug stability, improve penetration to intraocular tissues, and reduce dosing frequency, collectively offering new opportunities for non-surgical cataract management. While preclinical findings are promising, further clinical studies are essential to evaluate long-term safety, efficacy, and scalability. As research progresses, these advanced delivery systems hold the potential to complement existing surgical treatments, reduce cataract-related visual impairment, and improve patient outcomes, particularly in underserved populations worldwide.

References

1. Giri BR, Jakka D, Sandoval MA, Kulkarni VR, Bao Q. Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies. **Pharmaceutics**. 2024;16(10):1325.
2. Ashtekar KS, Monde AA, Nilangekar P, Bagul U, Nazirkar M, Kokare C. A review on nanotechnology-based ophthalmic drug delivery systems. **J Drug Deliv Ther**. 2023;13(12):262-9.
3. Tian B, Bilsbury E, Doherty S, Teebagg S, Wood E, Su W, et al. Ocular Drug Delivery: Advancements and Innovations. **Pharmaceutics**. 2022;14(9):1931.
4. Chen Y, Ye Z, Chen H, Li Z. Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment. **Int J Nanomedicine**. 2024;19:4021–40.
5. Zhou Y, et al. Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. **Adv Healthc Mater**. 2024;13(3):e2304626.
6. Silva-Cunha A. Advances in Ocular Drug Delivery Systems. **Pharmaceutics**. 2021;13(9):1383.

7. Choursiya KA, Kandalkar SG, Shaikh SR, Gangurde PK, Jadhav KR, Nikam SM, Bachhav RS. Advancements In Ocular Drug Delivery System: A Comprehensive Review. **Int J Pharm Sci**. 2024;2(5):758–75.
8. Bhatt P, et al. Innovations in ocular drug delivery. **South Asian J Health Prof**. 2023;10(2):45–52.
9. Bisen PS, et al. A review on polymers in ocular drug delivery systems. **MedComm Biomater Appl**. 2024;3(1):e77.
10. Truscott RJ. Age-related nuclear cataract-oxidation is the key. *Exp Eye Res*. 2005 Mar;80(5):709-25. doi:10.1016/j.exer.2004.12.007.
11. Michael R, Bron AJ. The ageing lens and cataract: a model of normal and pathological ageing. *Philos Trans R Soc Lond B Biol Sci*. 2011 Jan 27;366(1568):1278-92. doi:10.1098/rstb.2010.0300.
12. Nagaraj RH, Sell DR, Prabhakaram M, Ortwerth BJ, Monnier VM. High correlation between pentosidine protein cross-links and fluorescence in human lens and skin in individual donors. *FEBS Lett*. 1991 Nov 18;290(1-2):115-9. doi:10.1016/0014-5793(91)81242-Z.
13. Azuma M, Shearer TR. The role of calcium in cataract formation. *Curr Eye Res*. 1993 Jul;12(7):653-7. doi:10.3109/02713689308999469.
14. Shiels A, Hejtmancik JF. Genetic origins of cataract. *Arch Ophthalmol*. 2007 Feb;125(2):165-73. doi:10.1001/archophth.125.2.165.
15. Michael R, van Marle J, Vrensen GF. Light microscopic and ultrastructural changes in the lens epithelium of human donor eyes after UV-B irradiation. *Invest Ophthalmol Vis Sci*. 2000 Oct;41(11):3148-57.
16. Zhang X, Li Y, Wang Y, et al. Cyclic cell-penetrating peptide-engineered ceria nanoparticles for non-invasive alleviation of ultraviolet radiation-induced cataract. *J Nanobiotechnol*. 2025;23(1):337.
17. Fayazbakhsh F, Hataminia F, Eslam HM, et al. Gold nanoparticles encapsulated resveratrol as an anti-aging agent to delay cataract development. *Sci Rep*. 2023;13(1):21344.
18. Cai R, Zhang L, Chi H. Recent development of polymer nanomicelles in the treatment of eye diseases. *Front Bioeng Biotechnol*. 2023;11:1246974
19. Wang Y, Hu Y, An J, Zhang H, Liu X, Li X, Zhang Z, Zhang X. Liposome-based permeable eyedrops for effective posterior segment drug delivery. *Adv Funct Mater*. 2024;34(39):2403142
20. Gu H, Chen P, Liu X, Lian Y, Xi J, Li J, Song J, Li X. Trimethylated chitosan-coated flexible liposomes with resveratrol for topical drug delivery to reduce blue-light-induced retinal damage. *Int J Biol Macromol*. 2023;252:126480.
21. Zhou Y, Zhang Y, Wang J, Li X, Li Y. Recent advances in nanomedicine for ocular fundus neovascularization disease management. *Adv Healthc Mater*. 2024;13(5):e2304626.
22. Tang H, Li X, Jin L, Dong J, Yang L, Li C, Zhang L, Cheng F. Applications and latest research progress of liposomes in the treatment of ocular diseases. *Biointerphases*. 2025;20(1):011005
23. Chaudhuri A, Gauttam VK, Arushi A, Negi S, Singh G, Bharti B, et al. Design and Evaluation of Novel in situ Gel Forming Ocular Drug Delivery System of Kaempferol for Sustain Pharmacological Response against Cataract. *Pharmacognosy Research*. 2025;17(1):173-184
24. Kotreka UK, Davis VL, Adeyeye MC. Development of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts. *PLoS One*. 2017;12(2):e0172306.
25. Gözcü S, et al. Formulation of hesperidin-loaded in situ gel for ocular drug delivery: a comprehensive study. *J Sci Food Agric*. 2024;104(5):1234-1242.
26. Kumara BN, Velmurugan K, Ghate MV, Shambhu R, Nirmal J, Prasad KS. A promising 'single' and 'dual' drug-nanocomposite enriched contact lens for the management of glaucoma in response to the tear fluid enzyme. *J Mater Chem B*. 2024;12(9):2394-2412.
27. Guo X, Sun Y, Qiao J, Fan B, Zhang X. Levofloxacin-loaded silicone contact lenses materials for ocular drug delivery. *J Biomater Appl*. 2025;39(5):1034-1042.
28. Torun L, Yildiz UH, Kocabas C. Microfluidic contact lenses for ocular diagnostics and drug delivery. *Nano Select*. 2023;4(1):1-14
29. Fitaihi R, Abukhamees S, Orlu M, Craig DQM. Transscleral delivery of dexamethasone-loaded microparticles using a dissolving microneedle array. *Pharmaceutics*. 2023;15(6):1622.
30. Wu Y, Vora LK, Donnelly RF, Singh TRR. Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye. *Drug Deliv Transl Res*. 2023;13(10):2142–2158.
31. Shi H, Huai S, Wei H, Xu Y, Lei L, et al. Dissolvable hybrid microneedle patch for efficient delivery of curcumin to reduce intraocular inflammation. *Int J Pharm*. 2023;643:123205.

32. Ashtekar KS, Monde AA, Nilangekar P, Bagul U, Nazirkar M, Kokare C. A review on nanotechnology-based ophthalmic drug delivery systems. *J Drug Deliv Ther.* 2023;13(12):262-9.